The apelin receptor system has recently emerged as an exciting new drug target. Come learn about the fascinating journey of this GPCR from the bench to the bedside at this symposium. The apelin receptor is an important player in various types of cardiovascular diseases including heart failure, metabolic syndrome and preeclampsia. Major pharmaceutical companies have recently initiated clinical trials targeting this receptor system. An international panel of experts will present cutting-edge research from their laboratories with an eye on drug development using peptides and small molecules.